Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22. Comparison with CD21 (complement receptor type 2/Epstein-Barr virus receptor)
- PMID: 2961806
Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22. Comparison with CD21 (complement receptor type 2/Epstein-Barr virus receptor)
Abstract
CD22 and CD21 are glycoproteins primarily expressed on normal and neoplastic human B cells. The surface expression of these two molecules parallel each other during normal B cell differentiation, and the reported relative mobilities for CD22 and CD21 are 130/140 kDa and 140 kDa, respectively. Herein we present a detailed analysis of the biosynthesis and structure of CD22 and also compare it directly to CD21. Electrophoresis under reducing and nonreducing conditions suggested that CD22 and CD21 may have similarities in intra-chain disulfide bond formation. Biosynthesis and processing of CD22 and CD21 were very similar with respect to kinetics and post-translational modification, and both could be phosphorylated. However, endoglycosidase digestion (using N-glycanase and endoglycosidase H) and peptide mapping (using V8 protease and N-chlorosuccinimide) strongly suggested that CD22 and CD21 are distinct gene products.
Similar articles
-
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S. Clin Cancer Res. 2003. PMID: 14506197
-
Characterization of a murine T cell surface disulfide-linked dimer of 45-kDa glycopeptides (YE1/48 antigen). Comparison with T cell receptor, purification, and partial amino acid sequences.J Immunol. 1988 Jan 1;140(1):161-9. J Immunol. 1988. PMID: 3121737
-
Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation.J Immunol. 1996 Nov 15;157(10):4390-8. J Immunol. 1996. PMID: 8906814
-
CD22 as a target of passive immunotherapy.Semin Oncol. 2003 Apr;30(2):253-7. doi: 10.1053/sonc.2003.50057. Semin Oncol. 2003. PMID: 12720147 Review.
-
CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.Semin Immunol. 1998 Aug;10(4):287-97. doi: 10.1006/smim.1998.0121. Semin Immunol. 1998. PMID: 9695185 Review.
Cited by
-
CD22 associates with the human surface IgM-B-cell antigen receptor complex.Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3236-40. doi: 10.1073/pnas.90.8.3236. Proc Natl Acad Sci U S A. 1993. PMID: 8475064 Free PMC article.
-
Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains.J Exp Med. 1993 Jul 1;178(1):139-49. doi: 10.1084/jem.178.1.139. J Exp Med. 1993. PMID: 8391059 Free PMC article.
-
A complex of glycoproteins is associated with VpreB/lambda 5 surrogate light chain on the surface of mu heavy chain-negative early precursor B cell lines.J Exp Med. 1993 Aug 1;178(2):469-78. doi: 10.1084/jem.178.2.469. J Exp Med. 1993. PMID: 8340754 Free PMC article.
-
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.Nat Rev Drug Discov. 2021 Mar;20(3):217-243. doi: 10.1038/s41573-020-00093-1. Epub 2021 Jan 18. Nat Rev Drug Discov. 2021. PMID: 33462432 Free PMC article. Review.
-
cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.J Exp Med. 1991 Jan 1;173(1):137-46. doi: 10.1084/jem.173.1.137. J Exp Med. 1991. PMID: 1985119 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources